News

Press Releases

Nov 14, 2025

SanegeneBio Announces Phase 1 Clinical Data for SGB-9768 Presented at ASN Kidney Week 2025

Nov 10, 2025

SanegeneBio and Innovent Announce Phase 1 Clinical Data for SGB-3908 Presented at American Heart Association (AHA) 2025 Annual Meeting

Nov 8, 2025

SanegeneBio Announces RNAi Licensing and Research Collaboration with Lilly

Oct 29, 2025

SGB-9768 Clinical Data to be Reported at ASN Kidney Week 2025

Oct 21, 2025

SanegeneBio Announces FDA Orphan Drug Designation for SGB-9768, an Experimental RNAi Medicine Targeting C3 mRNA

Sep 28, 2025

SanegeneBio Receives NMPA Approval to Initiate Clinical Trial of SGB-3383 for Complement-Mediated Blood Disorders

Sep 24, 2025

SanegeneBio to Present at RNA Leaders APAC 2025 & OTS 2025

Aug 25, 2025

SanegeneBio Healthcare Conferences This September

June 30, 2025

SanegeneBio Announces First Patient Dosed in Phase 1 Trial of SGB-3383

June 20, 2025

SanegeneBio to Present at the American Diabetes Association (ADA) 85th Scientific Sessions